Page 79 - Read Online

Ruff et al. Hepatoma Res 2023;9:37 https://dx.doi.org/10.20517/2394-5079.2023.51 Page 9 of 10

Copyright
© The Author(s) 2023.

REFERENCES
1. Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver 2017;11:13-26. DOI PubMed PMC
2. Gad MM, Saad AM, Faisaluddin M, et al. Epidemiology of cholangiocarcinoma; United States incidence and mortality trends. Clin
Res Hepatol Gastroenterol 2020;44:885-93. DOI
3. Patel N, Benipal B. Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 States.
Cureus 2019;11:e3962. DOI PubMed PMC
4. Alabraba E, Joshi H, Bird N, et al. Increased multimodality treatment options has improved survival for hepatocellular carcinoma but
poor survival for biliary tract cancers remains unchanged. Eur J Surg Oncol 2019;45:1660-7. DOI
5. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010;362:1273-81. DOI
6. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma-evolving concepts and therapeutic strategies. Nat Rev
Clin Oncol 2018;15:95-111. DOI PubMed PMC
7. Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun
2021;27:100354. DOI PubMed
8. Squires MH, Cloyd JM, Dillhoff M, Schmidt C, Pawlik TM. Challenges of surgical management of intrahepatic cholangiocarcinoma.
Expert Rev Gastroenterol Hepatol 2018;12:671-81. DOI PubMed
9. Santoni M, Rizzo A, Kucharz J, et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer
patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immun 2023;72:1365-79. DOI
10. Rizzo A, Brandi G. First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: "and yet it moves!"
Cancer Treat Res Commun 2021;27:100335. DOI PubMed
11. Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer
2016;122:3838-47. DOI
12. Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential
therapeutic targets. J Gastrointest Oncol 2019;10:652-62. DOI PubMed PMC
13. Rodrigues PM, Olaizola P, Paiva NA, et al. Pathogenesis of cholangiocarcinoma. Annu Rev Pathol 2021;16:433-63. DOI
14. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have
different outcomes. Gastroenterology 2013;144:829-40. DOI PubMed PMC
15. Wu MJ, Shi L, Merritt J, Zhu AX, Bardeesy N. Biology of IDH mutant cholangiocarcinoma. Hepatology 2022;75:1322-37. DOI
PubMed
16. Valls C, Gumà A, Puig I, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 2000;25:490-6. DOI
17. Seo N, Kim DY, Choi JY. Cross-sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis.
AJR Am J Roentgenol 2017;209:W64-75. DOI PubMed
18. Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med
2016;21:373-80. PubMed
19. Clark O, Yen K, Mellinghoff IK. Molecular pathways: isocitrate dehydrogenase mutations in cancer. Clin Cancer Res 2016;22:1837-
42. DOI PubMed PMC
20. Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res
Commun 2021;27:100356. DOI PubMed
21. Zhang W, Zhou H, Wang Y, et al. Systemic treatment of advanced or recurrent biliary tract cancer. Biosci Trends 2020;14:328-41.
DOI
22. Brandi G, Rizzo A. IDH inhibitors and immunotherapy for biliary tract cancer: a marriage of convenience? Int J Mol Sci
2022;23:10869. DOI PubMed PMC
+
23. Kohanbash G, Carrera DA, Shrivastav S, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8 T cell accumulation in
gliomas. J Clin Invest 2017;127:1425-37. DOI PubMed PMC
24. Klemm F, Maas RR, Bowman RL, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific
alterations of immune cells. Cell 2020;181:1643-60.e17. DOI PubMed PMC
25. Bunse L, Pusch S, Bunse T, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med
2018;24:1192-203. DOI
26. Wu MJ, Shi L, Dubrot J, et al. Mutant IDH inhibits IFNγ-TET2 signaling to promote immunoevasion and tumor maintenance in
cholangiocarcinoma. Cancer Discov 2022;12:812-35. DOI PubMed PMC
27. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas
and share hypermethylation targets with glioblastomas. Oncogene 2013;32:3091-100. DOI PubMed PMC
28. Rizzato M, Brignola S, Munari G, et al. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving
systemic chemotherapy: the BITCOIN study. Eur J Cancer 2022;166:165-75. DOI
29. Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying